Article

Antidepressants for Depression in Patients with Dementia: A Review of the Literature

The Consultant pharmacist: the journal of the American Society of Consultant Pharmacists 04/2014; 29(4):254-63. DOI: 10.4140/TCP.n.2014.254
Source: PubMed

ABSTRACT

Objective: To evaluate the literature investigating the efficacy and safety of antidepressants for treating depression in individuals with dementia.Data Sources: A literature search was conducted using MEDLINE, PUBMED, EMBASE, and Cochrane databases from inception to May 2013 for
studies in English that evaluated the treatment of depression in patients with dementia. All relevant randomized controlled trials (RCTs) and meta-analyses were identified using the search terms “dementia” or “Alzheimer's disease,” and “depression” or “major
depressive disorder.” Reference lists from retrieved articles and practice guidelines were also searched for relevant literature.Study selection and data extraction: Only randomized, placebo-controlled trials and meta-analyses that compared an antidepressant with placebo for the
treatment of depression in patients with dementia were included.Data Synthesis: In this systematic review, 10 RCTs and 3 meta-analyses were identified that examined the efficacy and safety of antidepressants compared with placebo in treating depression in patients with dementia. The majority
of the RCTs consisted of a small sample size, and the antidepressants studied were not routinely used in practice.Conclusions: The evidence for antidepressants in the treatment of depression in patients with dementia is inconclusive. The accumulation of evidence suggests nonpharmacologic
approaches and watchful waiting be attempted for the first 8 to 12 weeks in a patient who presents with both mild-to-moderate depression and dementia. In cases of severe depression, or depression not managed through nonpharmacologic means, a trial of an antidepressant may be initiated. However,
further well-designed trials are needed to support these recommendations.

Download full-text

Full-text

Available from: Christine Leong, Apr 14, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Behandlung mit Psychopharmaka im Rahmen psychischer Erkrankungen ist auch bei Menschen im höheren Lebensalter ein wichtiger Baustein der multimodalen Therapie. Aufgrund verschiedener Faktoren ist diese Medikation bei älteren Patienten allerdings mit einem erhöhten Auftreten unerwünschter Arzneimittelwirkungen assoziiert.
    No preview · Article · Oct 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuropsychiatric signs are critical in primary caregiving of Alzheimer patients and have not yet been fully inves tigated in murine models. 18-month-old 3×Tg-AD male mice and their wild-type male littermates (non-Tg) were used. The open field test and the elevated plus maze test were used to evaluate anxiety-like behaviors, whereas the Porsolt forced swim test, the tail suspension test, and the sucrose preference test for antidepressant/depression-coping behaviors. Neurochemical study was conducted by microdialysis in freely-moving mice, analyzing the basal and K(+)-stimulated monoamine output in the frontal cortex and ventral hippocampus. Moreover by immunohistochemistry, we analysed the expression of Tyrosin hydroxylase and Tryptophan hydroxylase, which play a key role in the synthesis of monoamines. Aged 3×Tg-AD mice exhibited a higher duration of immobility in the forced swim and tail suspension tests (predictors of depression-like behavior) which was not attenuated by a noradrenaline reuptake inhibitor, desipramine. In the sucrose preference test, 3×Tg-AD mice showed a significantly lower sucrose preference compared to the non-Tg group, without any difference in total fluid intake. In contrast, the motor functions and anxiety-related emotional responses of 3×Tg-AD mice were normal, as detected by the open-field and elevated plus-maze tests. To strengthen these results, we then evaluated the monoaminergic neurotransmissions by in vivo microdialysis and immunohistochemistry. In particular, with the exception of the basal hippocampal dopamine levels, 3×Tg-AD mice exhibited a lower basal extracellular output of amines in the frontal cortex and ventral hippocampus and also a decreased extracellular response to K(+) stimulation. Such alterations occur with obvious local amyloid-β and tau pathologies and without gross alterations in the expression of Tyrosin and Tryptophan hydroxylase. These results suggest that 3×Tg-AD mice exhibit changes in depression-related behavior involving aminergic neurotrasmitters and provide an animal model for investigating AD with depression. © The Author 2015. Published by Oxford University Press on behalf of CINP.
    Full-text · Article · Oct 2014 · The International Journal of Neuropsychopharmacology
  • [Show abstract] [Hide abstract]
    ABSTRACT: For many chronic diseases, translational success using the animal model paradigm has reached an impasse. Using Alzheimer's disease as an example, this review employs a networks-based method to assess repeatability of outcomes across species, by intervention and mechanism. Over 75% of animal studies reported an improved outcome. Strain background was a significant potential confounder. Five percent of interventions had been tested across animals and humans, or examined across three or more animal models. Positive outcomes across species emerged for donepezil, memantine and exercise. Repeatable positive outcomes in animals were identified for the amyloid hypothesis and three additional mechanisms. This approach supports in silico reduction of positive outcomes bias in animal studies.
    No preview · Article · Nov 2014 · Drug Discovery Today
Show more